Sintx Valuation

<div class='circular--portrait' style='background:#8B008B;color: #ffffff;font-size:3em;padding-top: 38px;;'>AMD</div>
AMDDW -- USA Stock  

USD 0.0101  0.0059  36.88%

What is the acquisition price tag of Sintx? Sintx seems to be overvalued based on Macroaxis valuation methodology. Our model measures the value of Sintx from inspecting the company fundamentals such as return on equity of (111.88) %, operating margin of (98.46) %, and price to book of 0.16 X as well as reviewing its technical indicators and Probability Of Bankruptcy. In general, we recommend buying undervalued stocks and disposing overvalued stocks since, at some point, asset prices and their ongoing real values will draw towards each other.

Search Valuation

 
Refresh
Sintx Valuation Module provides a unique way to ballpark how much the company is worth today. It is done using both, our quantitative analysis of the company fundamentals as well as its intrinsic market price estimation to project the real value. We also take into consideration other essential factors such as Sintx's management style, its c-level domain expertise and tenure, its overall leadership history as well as current capital structure, and future earnings potential.

Sintx Valuation Ratios as Compared to Competition

Comparative valuation techniques use various fundamental indicators to help in determining Sintx's current stock value. Our valuation model uses many indicators to compare Sintx value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Sintx competition to find correlations between indicators driving Sintx's intrinsic value. More Info.
Sintx is rated below average in price to book category among related companies. It is rated below average in price to sales category among related companies fabricating about  0.38  of Price to Sales per Price to Book. The ratio of Price to Book to Price to Sales for Sintx is roughly  2.67 

About Sintx Valuation

The Macroaxis Equity Valuation Mechanism determines the current worth of Sintx on a weekly bases. We use both absolute as well as relative valuation methodologies to arrive at the intrinsic value of Sintx. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Sintx based exclusively on its fundamental and basic technical indicators. By analyzing Sintx's financials, quarterly and monthly indicators, and its related drivers such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of Sintx's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Sintx. We calculate exposure to Sintx's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Sintx's related companies.
Amedica Corporation, a biomaterial company, develops, manufactures, and commercializes a range of medical devices based on its silicon nitride technology platform in the United States, Europe, and South America. Amedica Corporation was founded in 1996 and is headquartered in Salt Lake City, Utah. Amedica Corp is traded on BATS Exchange in USA.
Follow Benchmarks with Macroaxis syndicated feed, custom widget, or your favorite custom stock ticker
Please continue to Trending Equities. Please also try Global Correlations module to find global opportunities by holding instruments from different markets.
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page